# Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

> **NCT06875128** · PHASE2 · RECRUITING · sponsor: **Delcath Systems Inc.** · enrollment: 90 (estimated)

## Conditions studied

- Metastatic Breast Cancer in the Liver

## Interventions

- **DRUG:** Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)
- **DRUG:** Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)

## Key facts

- **NCT ID:** NCT06875128
- **Lead sponsor:** Delcath Systems Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-29
- **Primary completion:** 2029-05
- **Final completion:** 2029-08
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06875128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06875128, "Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06875128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*